The Supreme Cannabis Company announced the launch of Cambium Plant Sciences, located in Goderich, Ontario. Cambium, a wholly-owned subsidiary of Supreme Cannabis, aims to lead the agricultural revolution of cannabis genetics, to benefit consumer experiences and cultivation economics across the global cannabis industry.
"With the systematic application of research, technology and science, Cambium will focus on developing the next generation of premium cannabis genetics for recreational, medical and wellness applications. Cambium's mission is to supply agriculturally-focused, disease resistant, seed stock to the rapidly growing global cannabis market," the company explains.
"Cambium will develop cultivars that benefit our in-house brands, as well as our domestic and global cultivation and manufacturing partners. Initially, Cambium is expected to benefit from 7ACRES' established genetics, existing infrastructure and the unparalleled plant knowledge of its team," says Navdeep Dhaliwal, CEO of Supreme Cannabis.
Leading Cambium as General Manager is Dr. Alan Darlington. Dr. Darlington joined Supreme Cannabis' wholly-owned subsidiary, 7ACRES as the Director of Special Projects, where he has been improving the agricultural performance of 7ACRES' award winning genetics. Dr. Darlington holds a PhD from the University of Guelph in greenhouse systems and has over 30 years of experience leading and working with diverse multidisciplinary teams to develop plant-based IP.
"Cannabis has not yet had the benefit of the agricultural revolution that transformed commercial agriculture on a global scale over the past century. From the next blockbuster recreational strain, to disease resistant agricultural seed stock, Cambium will seek to improve the economic profile of cannabis production by pushing the boundaries of the cannabis plant," says Dr. Alan Darlington, General Manager of Cambium.
According to the company, Supreme Cannabis will invest approximately $14 million to develop a world leading facility for cannabis-focused research and innovation. "The Cambium facility will include the development of proprietary growing rooms for testing and selection of new genetics, breeding rooms for the creation of new seed stock, and supporting infrastructure in the existing 34,000 sqft facility. We expect to commence the retrofitting of the Cambium facility in the early summer of 2019 and Cambium has commenced the Health Canada licensing process," the company concludes.
For more information:
Supreme Cannabis
202 – 20 De Boers Dr, Toronto ON
M3J 0H1
Phone: (416) 630-7272
info@supreme.ca
supreme.ca